Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene + abemaciclib versus fulvestrant + abemaciclib in ESR1-mutant advanced breast cancer
MOH_2023-08-16_012876Phase 3Recruiting
- Sponsor
- Sermonix Pharmaceuticals
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Lasofoxifene + abemaciclib with Fulvestrant + abemaciclib (2 arms). Started Aug 2023; status: recruiting.
02
Drugs
lasofoxifeneabemaciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-08-16_012876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-16_012876.